Skip to main content
Premium Trial:

Request an Annual Quote

Arcis Licenses Sample Prep Technology to microRNA Diagnostics Firm Mirnax Biosens

NEW YORK — Arcis Biotechnology has signed an agreement to license its nucleic acid sample preparation and preservation technology to Spanish microRNA diagnostics developer Mirnax Biosens, the companies said today.

Under the terms of the deal, Mirnax will use Arcis' technology to improve the stability of miRNA biomarkers for early disease detection. The firms will also work together to develop a microfluidic device that integrates their respective technologies.

Additional terms were not disclosed.

"This latest agreement demonstrates the wide breadth of applications for our nucleic acid sample preparation technology including clinical diagnostics, which is an area that we look forward to exploring further," Arcis CSO Jan Rogers said in a statement.

Earlier this month, UK-based Arcis inked a distribution agreement for its sample prep products with Opentrons, and in May it formed a comarketing partnership with Andrew Alliance. In late 2018, Arcis licensed its technology to Teleflex for use in the development of a diagnostic assay.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.